title: Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
abstract: Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to ≥60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 μg. FBT uses the OraVescent technology to further increase the rate and extent of absorption of fentanyl. Short-term, randomized, controlled, clinical studies of FBT in patients with cancer pain have shown the efficacy of FBT in the management of breakthrough cancer pain. The efficacy was also confirmed in long-term studies on the safety and tolerability of FBT. It has been recommended that administration should be tailored to the patient's individual requirement, through dose titration starting from the lowest dose to find the effective dose. However, recent studies have demonstrated that predictable doses calculated from the basal opioid regimen are safe and more effective than doses achieved after dose titration.
authors.affiliation: Pain Relief and Supportive Care Unit, La Maddalena Cancer Center, Palermo, Via San Lorenzo 312, 90146 Palermo, Italy.
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Mercadante
mesh_terms: D000278:Administration, Buccal; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D059390:Breakthrough Pain / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D013607:Tablets / Q000008:administration & dosage*
chemical_list: D000701:Analgesics, Opioid; D013607:Tablets; D005283:Fentanyl
keywords: breakthrough cancer pain; cancer pain; fentanyl buccal tablet; opioids